DYNE THERAPEUTICS INC. - COMMON STOCK

11.94

13-March-25 09:26:02

15 minutes delayed

Stocks

-0.42

-3.44%

Today's range

11.92 - 12.63

ISIN

N/A

Source

NASDAQ

Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock

21 May 2024 19:39:57 By Nasdaq GlobeNewswire
Dyne Therapeutics Announces Proposed Public Offering of Common Stock

20 May 2024 15:01:00 By Nasdaq GlobeNewswire
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints

20 May 2024 05:30:06 By Nasdaq GlobeNewswire
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET

19 May 2024 07:00:00 By Nasdaq GlobeNewswire
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

02 May 2024 15:10:00 By Nasdaq GlobeNewswire
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer

27 Mar 2024 15:05:00 By Nasdaq GlobeNewswire
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium

27 Mar 2024 07:30:00 By Nasdaq GlobeNewswire
Dyne Therapeutics Announces CEO Transition

25 Mar 2024 06:30:00 By Nasdaq GlobeNewswire
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days

13 Mar 2024 06:30:00 By Nasdaq GlobeNewswire
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

05 Mar 2024 06:30:00 By Nasdaq GlobeNewswire
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference

14 Feb 2024 15:15:16 By Nasdaq GlobeNewswire
Dyne Therapeutics to Present at February Investor Conferences

01 Feb 2024 06:30:00 By Nasdaq GlobeNewswire
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

11 Jan 2024 15:05:00 By Nasdaq GlobeNewswire
Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

05 Jan 2024 06:30:00 By Nasdaq GlobeNewswire
Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock

04 Jan 2024 21:46:36 By Nasdaq GlobeNewswire
Dyne Therapeutics Announces Proposed Public Offering of Common Stock

03 Jan 2024 15:25:00 By Nasdaq GlobeNewswire
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases

03 Jan 2024 05:30:00 By Nasdaq GlobeNewswire
Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials

02 Jan 2024 15:05:00 By Nasdaq GlobeNewswire
Dyne Therapeutics to Present at November Investor Conferences

07 Nov 2023 06:30:00 By Nasdaq GlobeNewswire
Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones

30 Oct 2023 06:30:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.